Capital Market Last Updated at June 7, 2022 12:50 IST
https://mybs.in/2awFo6U
The drug maker announced that its wholly owned subsidiary, Eugia Pharma Specialties, received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Leuprolide Acetate injection, 14 mg/2.8 mL MDV (Kit).
The drug maker said the product will be a multiple-dose vials and it is therapeutically equivalent to the reference listed drug product (RLD), Lupron Injection,of AbbVie Endocrinology.
According to IQVIA, the approved product has an estimated market size of $83 million for the twelve months ending April 2022.
Aurobindo Pharma develops, manufactures and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients.
The company's consolidated net profit declined 28.1% to Rs 576.46 crore on a 3.3% fall in net sales to Rs 5,795.34 crore in Q4 FY22 over Q4 FY21.
Shares of Aurobindo Pharma were down 0.68% at Rs 519.25 on the BSE.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance. We, however, have a request. As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed. Support quality journalism and subscribe to Business Standard . Digital Editor
Copyrights © 2022 Business Standard Private Ltd. All rights reserved.
Business Standard is happy to inform you of the launch of "Business Standard Premium Services"
As a premium subscriber you get an across device unfettered access to a range of services which include:
Welcome to the premium services of Business Standard brought to you courtesy FIS. Kindly visit the Manage my subscription page to discover the benefits of this programme. Enjoy Reading! Team Business Standard